Home › Funds › OAKTREE CAPITAL MANAGEMENT LP › INDV

OAKTREE CAPITAL MANAGEMENT LP position in INDV

INDIVIOR PHARMACEUTICALS INC · Health Care

OAKTREE CAPITAL MANAGEMENT LP reported holding 6,127,212 shares of INDV (INDIVIOR PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$251.4M, representing 3.67% of its reported portfolio and ranking #7 among its reported holdings. OAKTREE CAPITAL MANAGEMENT LP has disclosed INDV holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)6.13M sh
Reported value held$251.40M
Portfolio Weight3.67%
First reportedQ1 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How OAKTREE CAPITAL MANAGEMENT LP's INDV position evolved

OAKTREE CAPITAL MANAGEMENT LP first disclosed a stake in INDV in Q1 2024 at 3,351,236 shares (US$71.7M). The position peaked in Q4 2025 at 7,108,644 shares, worth US$255.1M. Across 10 filings, OAKTREE CAPITAL MANAGEMENT LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,127,212 shares valued at US$251.4M — a reduction of -856,890 shares quarter over quarter.. Notable position changes include a 112% increase in Q3 2024, a 2242% increase in Q3 2025 (shares rose 49% over the following quarter), a 97% trim in Q4 2025 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 3.35M $71.71M New
Q2 2024 4.49M $70.43M Add
Q3 2024 9.52M $94.07M Add
Q4 2024 8.73M $112.00M Reduce
Q1 2025 11.01M $103.45M Add
Q2 2025 11.01M $162.27M Hold
Q3 2025 257.79M $10.69M Add
Q4 2025 7.11M $255.06M Reduce
Q1 2026 6.98M $212.88M Reduce
Q2 2026 6.13M $251.40M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About INDV and 13F data

INDV (INDIVIOR PHARMACEUTICALS INC) is a Health Care company. 53 other funds we track also report a position in INDV — the largest reported positions include Two Seas Capital LP (US$131.6M), Madison Avenue Partners, LP (US$117.9M), MANGROVE PARTNERS IM, LLC (US$109.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding INDV

All INDV fund holders →

FAQ

How long has OAKTREE CAPITAL MANAGEMENT LP held INDV?

OAKTREE CAPITAL MANAGEMENT LP has disclosed INDV holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is OAKTREE CAPITAL MANAGEMENT LP's current position in INDV?

As of Q2 2026, OAKTREE CAPITAL MANAGEMENT LP holds 6.13M shares of INDV (INDIVIOR PHARMACEUTICALS INC), valued at $251.40M, representing 3.67% of its reported portfolio and ranking #7.

Has OAKTREE CAPITAL MANAGEMENT LP been buying or selling INDV?

In the latest 13F filing (Q2 2026), OAKTREE CAPITAL MANAGEMENT LP reduced its position in INDV. The position peaked in Q4 2025 at 7.11M shares.

Which other funds hold INDV?

Other major institutional holders of INDV include Two Seas Capital LP, Madison Avenue Partners, LP, MANGROVE PARTNERS IM, LLC, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.